Subtype
Adrenal Medulla Neoplasm
CI-CAN-00001704Explore in graph →
Non-malignant27 active trials2 evidence items
- NCIt
- C4856
Loading cancer entity…
Subtype
CI-CAN-00001704Explore in graph →
Clinical trials
127 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06233903 | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System | withdrawn | Phase 2 | 0 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)INDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT04276597 | Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.(PUTNET) | withdrawn | Phase 2 | 0 | Excel Diagnostics and Nuclear Oncology Center |
| 1 |
| Mar 10, 2023 |
| clinicaltrials |
| NCT03923257 | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents | withdrawn | Phase 1 / Phase 2 | 0 | Sue O'DorisioOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 7, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jan 21, 2025source: clinicaltrials